Storm Therapeutics: Funding, Investors & Team (Sep 2026)
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.
Storm Therapeutics has raised $86.0M across 3 funding rounds on record, the most recent a Series C of $56.0M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Storm Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Storm Therapeutics Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Storm Therapeutics announced a Grant in May 2022; the amount was not disclosed.
7 months later, a Series B of $30.0M was announced in Dec 2022.
3.3 years later, a Series C of $56.0M was announced in Apr 2026.
Storm Therapeutics Founders and Leadership Team
Contact details for the Storm Therapeutics team: 1 of 3 have an email address on file.
Start 14-day free trial →Storm Therapeutics Funding Compared to Other Biotechnology Startups
Storm Therapeutics' latest round of $56.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Storm Therapeutics in Biotechnology and Cambridge
Companies Similar to Storm Therapeutics
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Storm Therapeutics Funding FAQs
What does Storm Therapeutics do?
STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.
How much funding has Storm Therapeutics raised?
Storm Therapeutics has raised $86.0M across 3 rounds on record. The most recent is a Series C of $56.0M announced in Apr 2026.
When did Storm Therapeutics last raise funding?
Storm Therapeutics' most recent funding round on record is a Series C of $56.0M, announced in Apr 2026.
Who founded Storm Therapeutics?
FundedIQ lists Jerry Mcmahon (Founder) at Storm Therapeutics.
Who is the CEO of Storm Therapeutics?
Gerald Mcmahon is listed as CEO at Storm Therapeutics.
Where is Storm Therapeutics headquartered?
Storm Therapeutics is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Storm Therapeutics have?
Storm Therapeutics is in the 11-50 employee band.
How does Storm Therapeutics' funding compare to other Biotechnology startups?
Storm Therapeutics' latest round of $56.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Storm Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Storm Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.